MicroStrategy Incorporated (MSTR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MicroStrategy Incorporated d/b/a Strategy ('Strategy' or the 'Company') (NASDAQ: MSTR) investors concerning the Company's possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MICROSTRATEGY INCORPORATED (MSTR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On April 7, 2025, Strategy disclosed that, following its adoption of Accounting Standards Update No. 2023-08 ('ASU 2023-08'), which requires publicly traded companies to measure their crypto assets at fair value in their financial statements, it recognized a $5.91 billion unrealized loss on its digital assets for the first quarter 2025. The Company warned that it 'may not be able to regain profitability in future periods, particularly if [it] incur[s] significant unrealized losses related to [its] digital assets.'
On this news, Strategy's stock price fell $25.47, or 8.7%, to close at $268.14 per share on April 7, 2025, thereby injuring investors.
Then, on May 1, 2025, Strategy released its first quarter 2025 financial results, confirming that it had recorded an unrealized fair value loss on digital assets of approximately $5.9 billion due to applying a fair value accounting methodology to Strategy's bitcoin assets following bitcoin's depreciation in value during the first quarter of 2025.
Contact Us To Participate or Learn More:
If you purchased Strategy securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
S&P 500 Gains and Losses Today: Lululemon Stock Falls as Forecasts Reflect Consumer Caution
The S&P 500 added 1% on Friday, June 6, as a strong jobs report pointed to resilience in the labor market despite tariff-related concerns. After retreating from record highs over the past few sessions, shares of data analytics firm Palantir bounced back, boosted by a signal of robust AI demand. Shares of Lululemon plummeted after the apparel maker cut its outlook for the current quarter and the full year, citing soft consumer U.S. equities indexes pushed higher to close out the trading week. The Bureau of Labor Statistics reported that the U.S. economy added 139,000 jobs in May, topping economists' forecasts and helping alleviate concerns about a tariff-driven slowdown in the labor market. The S&P 500 gained 1% on Friday, closing above the 6,000-point level for the first time since February. The Dow was up 1.1%, while the Nasdaq jumped 1.2%. Shares of big data analytics software provider Palantir Technologies (PLTR) popped 6.5% higher, securing the top daily performance in the S&P 500. Positivity around its expanding government business helped lift Palantir to an all-time high on Tuesday, but before Friday's gains, the stock had been pulling back for a couple of sessions. Palantir and other artificial intelligence companies benefited from upbeat sentiment after earnings results from chipmaker Broadcom (AVGO) revealed strong AI demand. Moderna (MRNA) shares wrapped up a volatile week of trading with a gain of 5.1% on Friday. The biotech company announced at the end of last week that it had received Food and Drug Administration (FDA) approval for the use of its new COVID-19 vaccine by older and higher-risk patients. On Tuesday, Health and Human Services Secretary Robert F. Kennedy Jr. said Moderna had agreed to a placebo-controlled trial of the vaccine. United Airlines (UAL) announced a partnership with Spotify Technology (SPOT) that will allow airborne passengers to access playlists, audiobooks, and video podcasts from the streaming service on their seatback screens. United shares increased 4.8% on Friday, while rival carrier Delta Air Lines (DAL) shares were up 4.3%. Tesla (TSLA) shares advanced 3.7% on Friday as the feud between Tesla CEO Elon Musk and U.S. President Donald Trump showed signs of de-escalation heading into the weekend. The spat between the two contributed to a major drop in the electric vehicle (EV) maker's stock in the prior session. Several analysts reaffirmed their bullishness on Tesla despite the high-profile conflict, but they noted that the tensions with Trump could complicate the regulatory path for the firm's self-driving technology or risk alienating people with certain political perspectives. Lululemon Athletica (LULU) issued lower-than-expected sales and profit guidance for the current quarter and trimmed its full-year profit forecast. The maker of yoga attire and other athletic apparel noted that U.S. consumers are taking a cautious approach to spending and discussed plans to increase prices on some products as it aims to mitigate tariff impacts. Lululemon shares plunged 19.8% on Friday, dropping the most of any constituent in the S&P 500. JPMorgan and UBS analysts cut their price targets on Lululemon stock following the underwhelming outlook. Broadcom posted fiscal second-quarter sales and adjusted profit results that were roughly in line with consensus forecasts. A major year-over-year uptick in artificial intelligence semiconductor revenue helped the chipmaker achieve record quarterly revenue of $15 billion. However, Broadcom shares slipped 5% on Friday, receding from a string of record highs notched before the earnings release. Mosaic (MOS), a provider of fertilizers and other agricultural products, reduced its 2025 phosphate production guidance, citing operational issues at its U.S. facilities. Shares of Mosaic were down 4.4%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the 'Grant Date'), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact:Dominic Piscitelli, Chief Financial info@ sesión para acceder a tu cartera de valores
Yahoo
an hour ago
- Yahoo
Oceaneering Announces CFO Succession Plan
HOUSTON, June 06, 2025--(BUSINESS WIRE)--Oceaneering International, Inc. (NYSE: OII) ("Oceaneering") today announced a Chief Financial Officer ("CFO") succession plan. Alan R. Curtis, Senior Vice President & CFO, has announced his decision to retire from his position effective January 1, 2026. Mr. Curtis began his career with Oceaneering in 1995 as a Financial Controller and has served in a variety of roles, including most recently as CFO since 2015. Addressing Mr. Curtis's pending retirement, President and Chief Executive Officer Rod Larson said, "On behalf of all Oceaneers, I would like to extend our deep gratitude to Alan for his financial leadership and strategic insights over the past decade. Under his leadership, we have consistently delivered steady shareholder returns and significantly enhanced our portfolio, enabling us to 'solve the unsolvable' for our customers in the most challenging environments. His extensive knowledge of Oceaneering and commitment to operational excellence and talent development have been instrumental to our success, and we wish him the best in his well-deserved retirement." M. Kevin McEvoy, Chairman of Oceaneering's Board of Directors, added, "Since I hired Alan 30 years ago, he has demonstrated integrity and a natural curiosity about Oceaneering's diverse services, products, and capabilities. Through his passion for the business, he developed close partnerships with our segment leaders, leading initiatives that strengthened our financial and organizational framework, and that continue to drive our financial and technological growth." Michael W. Sumruld will join Oceaneering as Senior Vice President of Finance on September 1, 2025, and is expected to later succeed Mr. Curtis as CFO upon Mr. Curtis's retirement from such position. Mr. Curtis will continue to serve Oceaneering in a supporting role to provide for an orderly transition of duties. Mr. Sumruld will report to Mr. Larson. Mr. Sumruld most recently served as Senior Vice President and CFO for Parker Drilling Company from October 2017 until its sale to Nabors Industries Ltd. in March 2025. In that role, he managed the company's investor relations, corporate development, treasury, finance and accounting, tax, financial planning and analysis, compliance, operations integrity, and information technology organizations. Prior to his time at Parker Drilling Company, Mr. Sumruld held positions at LyondellBasell Industries N.V. and at Baker Hughes Incorporated. He is a certified public accountant and holds a bachelor's degree in accounting from the University of Houston and a Master of Business Administration from Texas A&M University. Regarding Mr. Sumruld's appointment, Mr. Larson said, "We are pleased to welcome Mike following a thoughtful succession planning process. I know Mike quite well from our work together at Baker Hughes on the North American offshore business, where he proved himself to be a strong, people-focused leader with a collaborative, business-oriented approach. The Board is excited that Mike will be joining the management team to drive Oceaneering's continued growth and shareholder value." Oceaneering is a global technology company delivering engineered services and products and robotic solutions to the offshore energy, defense, aerospace, and manufacturing industries. For more information, please visit View source version on Contacts Hilary FrisbieSenior Director, Investor Relations713-329-4755investorrelations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
